Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Remote Patient Monitoring with Digital Medicine Society

The Digital Medicine Society (DiMe) is a global nonprofit specializing in the advancement of ethical, effective, equitable, and safe use of digital technology for redefining healthcare and optimizing lives. Jennifer Goldsack, CEO of DiMe, spoke with Intel’s Head of Global Health Solutions Alex Flores on the advancements in remote patient monitoring and the role…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The Digital Medicine Society (DiMe) is a global nonprofit specializing in the advancement of ethical, effective, equitable, and safe use of digital technology for redefining healthcare and optimizing lives. Jennifer Goldsack, CEO of DiMe, spoke with Intel’s Head of Global Health Solutions Alex Flores on the advancements in remote patient monitoring and the role technology plays in this.

Remote patient monitoring allows parsing out different digital phenotypes within certain disease states to effectively match treatment with the patient. Goldsack says, “In those broad disease states, where there’s very little that we can do to either ameliorate symptoms of the disease or cure the disease — something like Parkinson’s or Alzheimer’s disease. We’re hopeful that these new measures can start to advance the field.”

Goldsack believes there is a much more practical reason for remote patient monitoring to become an essential focus of care: the evolving role and methods of healthcare today.

“We must start thinking about how we can start to monitor people’s health outside the clinic walls,” she explains. “How can we think about patients with complex chronic diseases who may have episodic conditions with flare-ups? How can we monitor their well-being and health performance under clinicians’ care without bringing them into the hospital every time?”

The reality that healthcare presently faces is a shortage of doctors and clinicians to treat the number of patients. Remote patient care is one healthcare solution that helps ensure the patient gets the best care possible, even with reduced resources available. “We can use remote patient monitoring to get early signals… [and] we can intervene and care for them before those outcomes become bad and before they become pricey,” Goldsack says.

The technology behind remote patient monitoring must be high quality to make high-quality clinical decisions. Clinical validation of the gathered data is vital in this process. Goldsack says it’s also crucial that the technology deployed is an affordable solution, because if it isn’t, then it won’t be sustainable.

In terms of utilizing AI in the remote patient monitoring process, Goldsack says there is unlimited potential. Still, it is important to keep things in perspective and focus on the most critical challenges first. “We should look at the ability to identify particular phenotypes within large population-level data sets,” she notes. “AI might be able to tell us if we deliver the right data that some patients do well, and for whatever reasons, some patients end up having a fall and an injury and come back into the hospital within four weeks. It might be that we have no idea what the differences are between those patients who fall and those who don’t.” AI could help make those determinations.

Learn more about remote patient monitoring by connecting with Jennifer Goldsack or Alex Flores on LinkedIn or visit: 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Health and Life Sciences at the Edge.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512